The IMID Forum

Professor Leonard Calabrese presents the Day 3 highlights of the key abstracts and posters presented at ACR 2021.

Grace Wright presents the Day 2 highlights of the key abstracts and posters presented at ACR 2021.

Prof Iain McInnes discusses the risk of herpes zoster in RA patients taking biologics and DMARDS. He also discusses reactivation of hepatitis B in patients with RA taking tofacitinib. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Prof Calabrese presents the Day 1 highlights of the key abstracts and posters presented at ACR 2021.

A preview of the latest research at ACR 2021. Prof Ritchlin highlights important abstracts in cytokine signalling at the upcoming ACR Convergence.

Paul Bird, Conjoint Professor at the University of South Wales. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Paul Bird assess the real‑world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia.

Prof Iain McInnes discusses poor prognostics factors from the FINCH 3 study, and the effectiveness and persistence of monotherapy and combination therapy from the Australian OPAL study. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Kurt de Vlam, Professor of Rheumatology at UZ Leuven, Belgium. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor de Vlam assess the impact of baseline pain severity on pain response and the time to improvement in patients with PsA receiving tofacitinib.

Vibeke Strand, Adjunct Clinical Professor in the Division of Immunology/Rheumatology, Biopharmaceutical Consultant at Stanford University School of Medicine. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Strand discusses improvements in PROs in patients with RA treated with upadacitinib monotherapy.

Prof Iain McInnes discusses an essential part of the assessment of patients with rheumatic diseases; patient reported outcomes, or PROs. Improving PROs is crucial to effect tangible change in diseases and patient outcomes - to the extent that PROs are now included as an important component of many clinical trials. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.